NEW YORK, Jan 4, 2026, 14:49 ET — Market closed
- Johnson & Johnson board declared a $1.30-per-share quarterly dividend, payable March 10.
- JNJ shares last closed at $207.35 on Jan. 2, up 0.19%.
- Next catalyst is the company’s Jan. 21 fourth-quarter earnings call, with U.S. jobs and inflation data due earlier in the month.
Johnson & Johnson on Friday declared a quarterly cash dividend of $1.30 per share, payable March 10 to shareholders of record at the close of business on Feb. 24, the company said. The ex-dividend date — when shares begin trading without the right to that payout — is also Feb. 24. 1
At Friday’s close, the payout implies an annual dividend yield of about 2.5%, keeping the healthcare bellwether in focus for income investors as U.S. trading resumes on Monday. Dividend schedules can influence near-term positioning when funds rebalance early-year portfolios.
The next major company catalyst is Jan. 21, when Johnson & Johnson will host its fourth-quarter earnings call at 8:30 a.m. ET. Traders will also be parsing U.S. data, with the employment report due Jan. 9 and the consumer price index set for Jan. 13. 2
JNJ shares last closed up 0.19% at $207.35 on Jan. 2, with about 6.33 million shares traded. The stock is up about 43.8% over the past year and sits roughly 3.6% below its 52-week high, according to Investing.com data. 3
On the chart, traders are watching whether the stock can hold above its 50-day moving average near $200, a level often treated as a near-term support marker. J&J is also well above its 200-day moving average around $174, a longer-term trend gauge for many investors. 4
Earnings will put the focus back on 2026 guidance, momentum in the company’s drug and medical-device businesses, and any update on pricing and competitive pressures across key franchises. Investors will also listen for management’s commentary on margins and currency effects, which can swing quarter-to-quarter comparisons.
With jobs and inflation readings returning to the calendar, rate expectations are back in play. That matters for steady dividend payers like Johnson & Johnson because their relative appeal tends to rise when investors expect lower interest rates and seek predictable cash returns.
One risk is litigation. A Baltimore jury in late December awarded more than $1.5 billion in a talc-related case, and J&J’s worldwide vice president of litigation Erik Haas said the company would “immediately appeal” the verdict. 5
With U.S. markets shut for the weekend, investors head into Monday balancing the dividend backdrop against a busy January of macro data and earnings. For Johnson & Johnson stock, the next hard catalyst is the Jan. 21 quarterly report and call.
